COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany

References

• World Health Organization. The top 10 causes of death. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Published December 9 2020. Accessed April 24, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2021 Report); 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed February 5, 2021.
   Google Scholar
• Han MK, Agusti A, Celli BR, et al. From global initiative for chronic obstructive lung disease stage 0 to pre-chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2021;203(4):414–423.
   PubMed Web of Science ®Google Scholar
• Gibson GJ, Loddenkemper R, Sibille Y, et al. The European Lung White Book. Respiratory health and disease in Europe: Ch 2 the economic burden of lung disease. Available from: https://www.erswhitebook.org/files/public/Chapters/02_economics.pdf. Accessed December 4, 2020.
   Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.00014304
   PubMed Web of Science ®Google Scholar
• Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421–438. doi:10.1016/j.ccm.2020.06.007
   PubMed Web of Science ®Google Scholar
• Cardoso J, Coelho R, Rocha C, Coelho C, Semedo L, Bugalho Almeida A. Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio. Int J Chron Obstruct Pulmon Dis. 2018;13:1105–1113. doi:10.2147/COPD.S155848
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Boland M, et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. Int J Chron Obstruct Pulmon Dis. 2017;12:3183–3194. doi:10.2147/COPD.S142378
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439–2450. doi:10.2147/COPD.S94259
   PubMed Web of Science ®Google Scholar
• Buhl R, Criée C-P, Kardos P, et al. A year in the life of German patients with COPD: the DACCORD observational study: two cohorts, observational, comparing patients on a treatment including LAMA or one not including LAMA. No intervention. 6000 patients in Germany, at 500 clinics. Int J Chron Obstruct Pulmon Dis. 2016;11:1639–1646. doi:10.2147/COPD.S112110
   PubMed Web of Science ®Google Scholar
• Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228. doi:10.1371/journal.pone.0101228
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Nuevo J, Telg G, et al. Real-life treatment patterns and burden of disease among patients with COPD - a large observational study. In proceedings of B41. therapeutic intervention, quality improvement, and treatment adherence in obstructive lung disease. American Thoracic Society; May, 2020:A3331–A3331.
   Google Scholar
• Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich F. Risk of future exacerbations among COPD patients – a real-world register-based cohort study in Germany. Abstracts zum 127. Kongress der Deutschen Gesellschaft für Innere Medizin e.V [Congress of the German Society for Internal Medicine e.V]. Internist (Berl). 2021;62(Suppl2):147–202. doi:10.1007/s00108-021-01036-7
   PubMedGoogle Scholar
• Vogelmeier C, Pignot M, Wiklund F, Nuevo J, Telg G, Janson C. Risk of future exacerbations among COPD patients – a real-world register-based cohort study (AvoidEx). Eur. Resp. J. 2020;09072020:4189. doi:10.1183/13993003.congress-2020.4189
   Google Scholar
• Vogelmeier CF, Diesing J, Kossack N, Pignot M, Friedrich F. P631 risk of future exacerbations among COPD patients ̶ a real-world register-based cohort study in Germany. In proceedings of 61. Kongresses der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Latebreaking Abstracts. Pneumologie. 2020;74(S01):S147. doi:10.1055/s-0037-1599663
   Google Scholar
• Birkeland KI, Bodegard J, Banerjee A, et al. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: a large multinational observational study. Diabetes Obes Metab. 2021;23(1):75–85. doi:10.1111/dom.14189
   PubMed Web of Science ®Google Scholar
• Dong H, Robison LL, Leisenring WM, Martin LJ, Armstrong GT, Yasui Y. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015;181(7):532–540. doi:10.1093/aje/kwu289
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• Vogelmeier CF, Kostikas K, Fang J, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178. doi:10.1186/s12931-019-1130-y
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203. doi:10.2147/copd.s3385
   PubMedGoogle Scholar
• Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–764. doi:10.2147/COPD.S36997
   PubMed Web of Science ®Google Scholar
• Wacker ME, Jörres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46. doi:10.1016/j.rmed.2015.12.001
   PubMed Web of Science ®Google Scholar
• Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156–1165. doi:10.1183/09031936.00038814
   PubMed Web of Science ®Google Scholar